Editorial orientation provided by MedAPI — not part of the coding instruction.
C02 covers primary malignant neoplasms arising in other or unspecified parts of the tongue, including the dorsal, lateral, and ventral surfaces; the anterior two-thirds when the precise subsite is not stated; the lingual tonsil; and overlapping tongue sites. Most anterior tongue lesions are managed as oral cavity cancers, whereas lingual tonsil tumors are generally considered oropharyngeal cancers. Malignancy confined to the base of tongue is classified separately.
Common Histologies
- Squamous cell carcinoma is by far the most common histology.
- Less common tumors include minor salivary gland carcinomas, lymphomas, sarcomas, and mucosal melanoma.
- Human papillomavirus–associated squamous cell carcinoma is particularly relevant to the lingual tonsil/oropharyngeal region and is less characteristic of conventional anterior oral tongue carcinoma.
Common Symptoms
- Persistent tongue ulcer (K12.1), plaque (K13.29), nodule (K13.70), or indurated mass (K13.79)
- Tongue pain (K14.6), burning (K14.6), bleeding (R58), or referred ear pain (H92.09)
- Dysarthria (R47.1), impaired tongue mobility (Q38.1), or difficulty chewing (R13.11)
- Dysphagia (R13.10) or odynophagia (R07.0)
- Unexplained weight loss (R63.4)
- Cervical lymphadenopathy, sometimes the presenting feature of lingual tonsil disease (R59.0)
Risk factors vary by subsite. Tobacco and heavy alcohol exposure are major risks for oral tongue squamous cell carcinoma, while HPV-associated disease is important in lingual tonsil tumors.
Diagnosis
Evaluation typically includes complete oral cavity and oropharyngeal examination, palpation of the tongue and neck, and flexible endoscopy when posterior extension is possible. Diagnosis requires tissue biopsy. Contrast-enhanced CT or MRI assesses local extent and cervical nodes; PET/CT may be used for advanced disease, suspected nodal involvement, or distant staging. Dental, nutritional, speech, and swallowing assessments are often obtained before treatment.
Staging
Staging depends on the anatomic site:
- Anterior oral tongue tumors are staged under oral cavity criteria, incorporating tumor size and depth of invasion, nodal disease, extranodal extension, and distant metastasis.
- Lingual tonsil tumors are staged as oropharyngeal cancers. HPV-mediated, p16-positive oropharyngeal squamous cell carcinoma has a distinct staging system from p16-negative disease.
Regional spread commonly involves cervical lymph nodes. Advanced lesions may invade the floor of mouth, intrinsic or extrinsic tongue musculature, mandible, or adjacent oropharyngeal structures.
Molecular Markers
- p16 immunohistochemistry is used as a surrogate marker for HPV-mediated squamous cell carcinoma in appropriate oropharyngeal tumors, including the lingual tonsil.
- Direct HPV testing may be performed according to pathology practice and clinical context.
- PD-L1 testing and broader molecular profiling may guide systemic therapy in recurrent or metastatic disease.
- Routine HPV-based classification should not be assumed for anterior oral tongue cancers.
Common Treatments
Treatment is determined by subsite, stage, resectability, pathology, and anticipated functional impact.
- Early oral tongue cancers are commonly treated with surgical excision or partial glossectomy, with neck management based on depth of invasion and nodal risk.
- Adjuvant radiation or chemoradiation may be indicated for adverse pathological features such as positive margins, extranodal extension, multiple involved nodes, perineural invasion, or lymphovascular invasion.
- Lingual tonsil cancers may be treated with radiation-based therapy, concurrent chemoradiation, or selected transoral surgery with neck dissection.
- Recurrent, unresectable, or metastatic disease may be treated with immunotherapy, chemotherapy, targeted systemic regimens, radiation, surgery, or symptom-directed supportive care.
- Rehabilitation may include swallowing therapy, speech therapy, nutritional support, dental care, and reconstruction after major resection.
Scope Note
C02 identifies the primary anatomic site of a malignant neoplasm within the included other or unspecified parts of the tongue. Its child codes distinguish selected tongue subsites, an overlapping lesion when no single site of origin can be determined, and an unspecified tongue site. C02 does not encode histology, HPV or p16 status, tumor grade, TNM stage, nodal involvement, distant metastasis, recurrence, or treatment status. Secondary malignant deposits involving the tongue are not coded as primary C02 tumors. Relevant tobacco history or alcohol abuse/dependence may require separate coding when documented.